3F8 is an antibody that attaches to neuroblastoma cells and
helps focus a patient’s own immune system - especially white
blood cells - to attack neuroblastoma cells. Conventional 3F8 is
made from mouse cells. In this study, investigators want to find
the optimal dose of humanized 3F8 (Hu3F8) that can be given with
the drug interleukin-2 (IL-2) in patients with neuroblastoma and
GD2-positive tumors that have continued to grow or have not
responded to standard therapy. Hu3F8 is made to be more like the
human immune system than a mouse’s immune system, so it may be
associated with fewer side effects in patients than standard
mouse-derived 3F8. Il-2 is a drug approved for treating melanoma
and kidney cancer, but its use in this study is considered
investigational. It works by activating the immune system.